Amgen to Present New Data Across Rare and Other Serious Autoimmune Diseases at ACR Convergence 2026 Could Emerging Therapies Improve Patient Care
The pharmaceutical industry is increasingly investing in targeted therapies to address rare serious autoimmune diseases. These conditions can cause persistent inflammation, organ damange, chronic pain, and other complications that affect patients quality of life. Advances in immunology and clinical research are creating opportunities to develop treatments that target specific disease mechanisms and improve long-term disease management.
On October 27, 2026, Amgen announced that it will present new clinical and real-world evidence across its portfolio at the American College of Rheumatology (ACR) Convergence 2026. The scientific programme includes Phase3 findings from studies involving dazodalibep in Sjogrens disease, UPLIZNA in IgG4-related disease, and real-world evidence for KRYTEXXA and TAVNEOS. These developments highlight the companys continued focus on rare and serious autoimmune conditions.

Amgens Latest Research Highlights Advances in Autoimmune Disease Treatment
Amgen is a biotechnology company developing and commercializing medicines for serious illnesses. Its research portfolio includes treatments targeting inflammatory, autoimmune, and other complex diseases.
The companys upcoming scientific presentations will cover clinical trial findings, long-term safety and efficacy data, and real-world treatment evidence. These studies aim to improve understanding of how therapies perform across different patient populations and clinical settings.
A major highlight is the Phase 3 OASIZ-301 study evaluating dazodailbep in adults with Sjogrens disease and moderate-to-severe systemic disease activity. The results are particularly relevant because patients with this condition may experience symptoms beyond dryness, including fatigue, chronic pain, neurological complications, and organ involvement.
Dazodalibep shows potential in Sjogrens Disease
Dazodalibep is an investigational CD40 ligand (CD40L) antagonist designed to interfere with immune-cell interactions involved in disease development. By targeting these pathways, the therapy aims to reduce abnormal immune activation associated with Sjogrens disease.
According to Amgen, the Phase 3 OASIZ-301 study showed improvements in systemic disease activity at Week 48 compared with placebo. Patients receiving dazodalibep at 1,500 mg every four weeks experienced a mean reduction of 5.6 points in the disease activity score, while those receiving 3,000 mg every 12 weeks experienced a reduction of 5.2 points. The placebo group recorded a reduction of 3.8 points.
The every-four-week regimen also improved patient-reported dryness compared with placebo on two assessment measures. Treatment-emergent adverse events, serious adverse events, and adverse events leading to treatment discontinuation occurred at similar rates across the study groups.
These findings could represent progress for people living with Sjogrens disease, for which approved treatment options remain limited. However, dazodalibep remains investigational, and its safety, effectiveness, and potential regulatory approval require continued assessment.
Real-World Evidence Expands Understanding of Existing Therapies
Beyond investigational treatment. Amgen plans to present real-world evidence for KRYSTEXX (pegloticase) in uncontrolled gout and TAVNEOS (avacopan) in ANCA-associated vasculitis.
KRYSTEXA is a biologic treatment for adults with chronic gout whose disease remains inadequately controlled with conventional uric acid-lowering therapies. The planned presentations include evidence concerning gout remission, treatment durability, and outcomes associated with immunomodulation.
Tavneos is an oral therapy used alongside standard treatment for adults with severe active ANCA-associated vasculitis, including granulomatosis with polyangiitis will examine treatment effectiveness and safety in clinical practice, as well as complications associated with prolonged moderate-to-high-dose glucocorticoid use.
Real-world evidence can complement randomized clinical trials by providing information about treatment patterns and outcomes in routine healthcare settings. However, observational findings may be influenced by differences in patient charateristics, treatment selection, and clinical practices.
Future Opportunities and Challenges in Autoimmune Disease Research
The growing focus on targeted reflect opportunities to develop more specific approaches to managing complex immune-mediated conditions. Research into immune-cell pathways, long-term treatment outcomes, and patient-reported symptoms could help guide future therapeutic development.
For Amgen, presenting evidence across investigational and established medicine may strengthen its understanding of treatment benefits and support future research priorities. These developments could also help healthcare professionals make more informed treatment decisions.
Real-world evidence can complement randomized clinical trials by providing information about treatment patterns and outcomes in routine healthcare settings. However, observational findings may be influenced by differences in patient charateristics, treatment selection, and clinical practices.
Conclusion
Amgens planned presentation at ACR Convergence 2026 highlights developments across Sjogrens disease, IgG4-related disease, uncontrolled gout, and ANCA-associated vasculitis.
The phase 3 dazodalibep findings, long-term UPLIZNA evidence, and real-world studies of KRYSTEXXA and TAVNEOS demonstrate the importance of evaluating both emerging therapies and established treatments.
Ultimately, the impact of these advances will depend on continued clinical evaluation, regulatory decisions, and their ability to deliver meaningful benefits to patients living with rare and serious autoimmune diseases.